体外连续传代诱导MRSA对泰地唑胺耐药的新rpoB突变
该研究通过对MRSA实验室菌株N315进行体外连续传代,筛选泰地唑胺耐药株,获得一株MIC为4 mg/L的表型稳定突变株;全基因组测序仅发现rpoB基因单核苷酸变异A1345G(D449N),并伴linezolid、chloramphenicol、retapamulin和quinupristin/dalfopristin的MIC升高≥2个log2稀释度,提示出现「PhLOPSa」耐药表型。
要点
- 体外传代10天获得泰地唑胺MIC 4 mg/L的稳定耐药MRSA突变株。
- 耐药株仅检出rpoB A1345G(D449N),为首个与PhLOPSa耐药相关的rpoB突变。
- 伴linezolid、chloramphenicol、retapamulin和quinupristin/dalfopristin交叉耐药。
核心结论
- rpoB突变A1345G(D449N)首次被提示与PhLOPSa类抗菌药物耐药相关,耐药机制可能为间接机制。
研究设计与样本
- 对MRSA实验室菌株N315进行体外连续传代筛选泰地唑胺耐药,对耐药株行全基因组测序和抗菌药物敏感性试验,并进行同源建模。
主要发现
- 连续传代10天后获得表型稳定的突变株,泰地唑胺MIC为4 mg/L。
- 全基因组测序仅发现rpoB单核苷酸变异A1345G,对应氨基酸替换D449N。
- linezolid、chloramphenicol、retapamulin和quinupristin/dalfopristin的MIC升高≥2个log2稀释度,提示PhLOPSa耐药表型。
- 包括rifampicin在内的其他药物敏感性基本不变。
- 同源模型提示突变残基不太可能直接影响oxazolidinone作用。
临床怎么用
- 对泰地唑胺耐药或PhLOPSa表型的MRSA,可关注rpoB等非经典耐药位点,并注意多重交叉耐药监测。
局限性
- 仅为体外传代获得的单一实验室菌株,耐药机制尚未明确,结论需临床菌株验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tedizolid is an oxazolidinone antimicrobial with activity against Gram-positive bacteria, including MRSA. Tedizolid resistance is uncommon and tedizolid's capacity to select for cross-resistance to other antimicrobials is incompletely understood. The objective of this study was to further explore the phenotypic and genetic basis of tedizolid resistance in MRSA. METHODS: We selected for tedizolid resistance in an MRSA laboratory strain, N315, by serial passage until an isolate with an MIC ≥1 log2 dilution above the breakpoint for resistance (≥2 mg/L) was recovered. This isolate was subjected to WGS and susceptibility to a panel of related and unrelated antimicrobials was tested in order to determine cross-resistance. Homology modelling was performed to evaluate the potential impact of the mutation on target protein function. RESULTS: After 10 days of serial passage we recovered a phenotypically stable mutant with a tedizolid MIC of 4 mg/L. WGS revealed only one single nucleotide variant (A1345G) in rpoB, corresponding to amino acid substitution D449N. MICs of linezolid, chloramphenicol, retapamulin and quinupristin/dalfopristin increased by ≥2 log2 dilutions, suggesting the emergence of the so-called 'PhLOPSa' resistance phenotype. Susceptibility to other drugs, including rifampicin, was largely unchanged. Homology models revealed that the mutated residue of RNA polymerase would be unlikely to directly affect oxazolidinone action. CONCLUSIONS: To the best of our knowledge, this is the first time that an rpoB mutation has been implicated in resistance to PhLOPSa antimicrobials. The mechanism of resistance remains unclear, but is likely indirect, involving σ-factor binding or other alterations in transcriptional regulation.
引用
- Shen T, Penewit K, Waalkes A, et al. Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage. J Antimicrob Chemother. 2021. PMID: 33057715. doi:10.1093/jac/dkaa422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。